Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CRLNASDAQ:INCYNASDAQ:MEDPNASDAQ:PPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLCharles River Laboratories International$145.24+0.1%$130.79$91.86▼$254.15$7.14B1.481.01 million shs632,963 shsINCYIncyte$68.27-0.8%$63.24$53.56▼$83.95$13.22B0.672.05 million shs1.74 million shsMEDPMedpace$302.69+1.6%$299.64$250.05▼$459.77$8.70B1.47365,467 shs656,130 shsPPDPPD$47.28$47.27$31.54▼$47.41$16.61B1.961.91 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLCharles River Laboratories International+0.09%-3.83%+2.74%-12.25%-30.75%INCYIncyte-0.78%-0.84%+6.99%+12.69%+11.12%MEDPMedpace+1.60%+0.13%-1.08%-5.30%-24.89%PPDPPD0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRLCharles River Laboratories International4.7145 of 5 stars3.15.00.04.72.32.51.9INCYIncyte4.4911 of 5 stars2.14.00.03.13.12.53.1MEDPMedpace4.4041 of 5 stars3.11.00.04.62.94.21.3PPDPPDN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRLCharles River Laboratories International 2.18Hold$171.8518.32% UpsideINCYIncyte 2.22Hold$74.539.17% UpsideMEDPMedpace 2.23Hold$349.3015.40% UpsidePPDPPD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INCY, MEDP, PPD, and CRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025INCYIncyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $107.006/3/2025INCYIncyteCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025INCYIncyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$61.005/27/2025INCYIncyteTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$72.00 ➝ $73.005/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.004/30/2025INCYIncyteWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $59.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRLCharles River Laboratories International$4.05B1.76$21.68 per share6.70$67.80 per share2.14INCYIncyte$4.24B3.12$0.55 per share123.32$17.90 per share3.81MEDPMedpace$2.11B4.12$13.95 per share21.70$26.56 per share11.40PPDPPD$4.68B3.55$1.99 per share23.71($1.21) per share-39.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRLCharles River Laboratories International$22.20M-$0.65N/A13.204.48-0.66%15.19%6.93%8/6/2025 (Estimated)INCYIncyte$32.62M$0.32213.3510.440.570.48%2.77%1.77%7/29/2025 (Estimated)MEDPMedpace$404.39M$13.1023.1122.165.4619.31%54.36%20.81%7/28/2025 (Estimated)PPDPPD$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/ALatest INCY, MEDP, PPD, and CRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion4/21/2025Q1 2025MEDPMedpace$3.06$3.67+$0.61$3.67$528.38 million$558.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/APPDPPDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRLCharles River Laboratories International0.781.431.16INCYIncyte0.012.042.00MEDPMedpaceN/A0.730.73PPDPPDN/A1.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRLCharles River Laboratories International98.91%INCYIncyte96.97%MEDPMedpace77.98%PPDPPD87.82%Insider OwnershipCompanyInsider OwnershipCRLCharles River Laboratories International1.30%INCYIncyte17.80%MEDPMedpace20.30%PPDPPD1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRLCharles River Laboratories International20,10049.12 million48.48 millionOptionableINCYIncyte2,617193.57 million159.12 millionOptionableMEDPMedpace5,90028.74 million22.91 millionOptionablePPDPPD26,000351.40 million344.72 millionNot OptionableINCY, MEDP, PPD, and CRL HeadlinesRecent News About These CompaniesMilwaukee Brewers at Chicago Cubs, ppd.June 19 at 3:58 AM | indystar.comBye bye, baby blue: Philly police are getting new uniforms. Not everyone is happy.June 18 at 10:57 PM | msn.comPittsburgh Pirates at Detroit Tigers, ppd.June 18 at 10:57 PM | indystar.comPost-Partum Depression Market Size | Drug Pipeline Analysis, Treatment, Trends, and Rising Global Prevalence 2025-2035June 18 at 6:21 AM | biznes.newseria.plWATCH: PPD arrests suspect allegedly reaching for gun at Pueblo No Kings rally (2)June 18 at 1:21 AM | msn.comPrichard police investigating officer’s use of non-issued baseball bat before arrestJune 18 at 1:21 AM | yahoo.comPPD: Woman arrested after reaching for gun at No Kings RallyJune 17 at 7:52 PM | fox21news.comPrichard police hold press conference after social media video sparks concernJune 17 at 7:52 PM | msn.comWATCH: PPD arrests suspect allegedly reaching for gun at Pueblo No Kings rallyJune 17 at 7:52 PM | msn.comTwo dozen firearms, meth, stolen items found in Pittsburg narcotics search, PPD saysJune 15, 2025 | msn.comPensacola police seek community help to expand real-time crime center without added costsJune 15, 2025 | msn.comPiedmont emergency crews tackle house fires and rollover crash Saturday nightJune 15, 2025 | msn.comPatterns of Psychiatric Medication Use in Postpartum DepressionJune 15, 2025 | physiciansweekly.comFour arrested in Hale County suspected of drug trafficking in Northwest TexasJune 14, 2025 | msn.comPPD: Two adults, two minors arrested in string of car theftsJune 14, 2025 | msn.comPPD: Natchitoches man pleads guilty to manslaughter for the death of Pineville residentJune 13, 2025 | msn.comPPD: Man arrested for DUI after crash that killed twoJune 13, 2025 | msn.comFour men arrested in Hale County drug bust, DPS saysJune 13, 2025 | msn.comPPD condemns marking of Reps, LG chairman’s houses for demolition over alleged cultismJune 12, 2025 | dailypost.ngBody of missing man recovered from Puyallup RiverJune 12, 2025 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINCY, MEDP, PPD, and CRL Company DescriptionsCharles River Laboratories International NYSE:CRL$145.24 +0.19 (+0.13%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$145.28 +0.05 (+0.03%) As of 06/18/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Incyte NASDAQ:INCY$68.27 -0.54 (-0.78%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$67.68 -0.58 (-0.86%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Medpace NASDAQ:MEDP$302.69 +4.77 (+1.60%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$300.00 -2.69 (-0.89%) As of 06/18/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.PPD NASDAQ:PPDPPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
